NASDAQ:RVMD Revolution Medicines (RVMD) Stock Forecast, Price & News $25.30 -1.61 (-5.98%) (As of 02:40 PM ET) Add Compare Share Share Today's Range$24.76▼$26.9850-Day Range$20.28▼$27.0052-Week Range$15.64▼$31.37Volume386,530 shsAverage Volume1.11 million shsMarket Capitalization$2.69 billionP/E RatioN/ADividend YieldN/APrice Target$33.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Revolution Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside31.0% Upside$33.00 Price TargetShort InterestBearish8.88% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.65Based on 2 Articles This WeekInsider TradingAcquiring Shares$2.05 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($3.47) to ($3.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector701st out of 981 stocksBiological Products, Except Diagnostic Industry115th out of 164 stocks 3.4 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.00, Revolution Medicines has a forecasted upside of 31.0% from its current price of $25.19.Amount of Analyst CoverageRevolution Medicines has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.88% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Revolution Medicines has recently decreased by 1.87%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 2.6 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Revolution Medicines this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have bought 4,857.24% more of their company's stock than they have sold. Specifically, they have bought $2,046,000.00 in company stock and sold $41,273.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Revolution Medicines is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.47) to ($3.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Revolution Medicines (NASDAQ:RVMD) StockRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address RVMD Stock News HeadlinesMay 24, 2023 | finance.yahoo.comRevolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation SummitMay 18, 2023 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Shares Down 5% June 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 18, 2023 | americanbankingnews.comAnalysts Set Revolution Medicines, Inc. (NASDAQ:RVMD) PT at $31.88May 13, 2023 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25%May 13, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Revolution Medicines, Inc. (NASDAQ:RVMD) Decreased by AnalystMay 11, 2023 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) PT Lowered to $35.00May 10, 2023 | finance.yahoo.comRevolution Medicines First Quarter 2023 Earnings: Beats ExpectationsJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate ProgressMay 9, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Revolution MedicinesMay 9, 2023 | finance.yahoo.comQ1 2023 Revolution Medicines Inc Earnings CallMay 8, 2023 | seekingalpha.comRevolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call TranscriptMay 8, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Xencor (XNCR) and Revolution Medicines (RVMD)May 3, 2023 | finance.yahoo.comWall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a BetMay 1, 2023 | finance.yahoo.comRevolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023May 1, 2023 | finance.yahoo.comRevolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy?April 25, 2023 | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives $32.25 Average Price Target from AnalystsApril 19, 2023 | finance.yahoo.comRevolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happyApril 17, 2023 | seekingalpha.comRevolution Medicines: Advancing On Several FrontsApril 16, 2023 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Revolution Medicines (NASDAQ:RVMD)April 15, 2023 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Trading 7.6% Higher April 14, 2023 | americanbankingnews.comHC Wainwright Weighs in on Revolution Medicines, Inc.'s Q1 2023 Earnings (NASDAQ:RVMD)April 13, 2023 | finance.yahoo.comRevolution Medicines to Participate in 22nd Annual Needham Healthcare ConferenceApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Revolution Medicines (RVMD) Buy RecommendationApril 12, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Revolution Medicines (RVMD)April 6, 2023 | finance.yahoo.comRevolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023See More Headlines RVMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Company Calendar Last Earnings5/08/2023Today6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees188Year FoundedN/APrice Target and Rating Average Stock Price Forecast$33.00 High Stock Price Forecast$38.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+29.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-248,710,000.00 Net Margins-744.36% Pretax Margin-745.57% Return on Equity-36.79% Return on Assets-31.00% Debt Debt-to-Equity RatioN/A Current Ratio16.89 Quick Ratio16.89 Sales & Book Value Annual Sales$35.38 million Price / Sales76.38 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book3.29Miscellaneous Outstanding Shares106,310,000Free Float97,276,000Market Cap$2.70 billion OptionableNot Optionable Beta1.44 Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 61)CEO, Pres & Chairman Comp: $1.01MMr. Jack Anders (Age 46)Chief Financial Officer Comp: $462.13kMs. Margaret A. Horn J.D. (Age 60)Chief Operating Officer Comp: $773.03kDr. Stephen M. Kelsey FRC Path. (Age 62)FRCP, M.D., Pres of R&D Comp: $773.03kMs. Xiaolin Wang (Age 52)Exec. VP of Clinical Devel. Comp: $582.43kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 42)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. David L. Pompliano Ph.D.Founding Chief Scientific OfficerMr. Walter Reiher Ph.D.Chief Information OfficerMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTBeam TherapeuticsNASDAQ:BEAMKrystal BiotechNASDAQ:KRYSImmunocoreNASDAQ:IMCRVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 533 shares on 5/26/2023Ownership: 0.016%Ameriprise Financial Inc.Bought 423,035 shares on 5/22/2023Ownership: 1.057%JPMorgan Chase & Co.Bought 666,584 shares on 5/18/2023Ownership: 3.069%New York State Common Retirement FundSold 5,902 shares on 5/18/2023Ownership: 0.046%Susquehanna International Group LLPBought 500 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RVMD Stock - Frequently Asked Questions Should I buy or sell Revolution Medicines stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks. What is Revolution Medicines' stock price forecast for 2023? 7 brokerages have issued 1 year price objectives for Revolution Medicines' shares. Their RVMD share price forecasts range from $23.00 to $38.00. On average, they anticipate the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts. How have RVMD shares performed in 2023? Revolution Medicines' stock was trading at $23.82 on January 1st, 2023. Since then, RVMD shares have increased by 6.7% and is now trading at $25.42. View the best growth stocks for 2023 here. When is Revolution Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our RVMD earnings forecast. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.12. The firm earned $7.01 million during the quarter, compared to the consensus estimate of $2.94 million. Revolution Medicines had a negative trailing twelve-month return on equity of 36.79% and a negative net margin of 744.36%. The company's revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.78) earnings per share. What ETFs hold Revolution Medicines' stock? ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL). When did Revolution Medicines IPO? (RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. What is Revolution Medicines' stock symbol? Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD." Who are Revolution Medicines' major shareholders? Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.81%), BlackRock Inc. (7.02%), EcoR1 Capital LLC (5.03%), Price T Rowe Associates Inc. MD (4.74%), BVF Inc. IL (4.66%) and Nextech Invest Ltd. (4.55%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, Jeanna Steele, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Revolution Medicines' stock price today? One share of RVMD stock can currently be purchased for approximately $25.42. How much money does Revolution Medicines make? Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $2.70 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. How many employees does Revolution Medicines have? The company employs 188 workers across the globe. How can I contact Revolution Medicines? Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com. This page (NASDAQ:RVMD) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.